Skip to content
2000
Volume 3, Issue 5
  • ISSN: 1568-0266
  • E-ISSN: 1873-4294

Abstract

The N-alkylated imino sugars have inhibitory activity against the first enzyme in the pathway for glucosylating sphingolipid in eukaryotic cells, ceramidespecific glucosyltransferase. A therapeutic approach termed ‘substrate deprivation’ or ‘substrate reduction therapy’ (SRT) aims to reduce biosynthetic capability in the cell to match the reduced lysosomal catalytic activity seen in lysosomal storage disorders. The use of N-alkylated imino sugars to establish this therapeutic strategy is described in cell culture and gene knockout mouse disease models. One imino sugar, N-butyl-DNJ (NB-DNJ) has been in clinical trials for type 1 Gaucher disease and has shown to be an effective therapy for this disorder.

Loading

Article metrics loading...

/content/journals/ctmc/10.2174/1568026033452483
2003-02-01
2024-11-05
Loading full text...

Full text loading...

/content/journals/ctmc/10.2174/1568026033452483
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test